Woodline Partners LP Zymeworks Inc. Transaction History

Woodline Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.43 $408,242 - $652,309	-87,794 Reduced 5.35%	1,554,082 $9.56 Million
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $2.77 Million - $4.42 Million	-574,186 Reduced 25.91%	1,641,876 $8.7 Million
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $5.75 Million - $16.3 Million	957,661 Added 76.1%	2,216,062 $14.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $19.1 Million - $36.9 Million	1,258,401 New	1,258,401 $20.6 Million
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $16.3 Million - $22.9 Million	-415,895 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $15.4 Million - $24.6 Million	-528,630 Reduced 55.97%	415,895 $19.4 Million
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $16.8 Million - $20 Million	500,191 Added 112.57%	944,525 $34.1 Million
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $4.16 Million - $8.53 Million	171,216 Added 62.69%	444,334 $15.8 Million
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $6.78 Million - $12.4 Million	273,118 New	273,118 $12.4 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $917M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.